Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms

Patent metadata

Field	Value
Publication number	US-11517553-B2
Application number	US-202017014041-A
Country	US
Kind code	B2
Filing date	Sep 8, 2020
Priority date	Jul 26, 2012
Publication date	Dec 6, 2022
Grant date	Dec 6, 2022

Abstract

A formulation, including: (a) a first medicament, wherein the first medicament includes an isothiocyanate functional compound/surfactant; and (b) a second medicament, wherein the second medicament includes an antineoplastic agent, such as a cytotoxic antineoplastic agent and/or a targeted antineoplastic agent.

First claim

What is claimed and desired to be secured by Letters Patent of the United States is:

1. A medicament formulation, comprising:
a first medicament, wherein the first medicament comprises an isothiocyanate functional compound; and
a second medicament, wherein the second medicament comprises an antineoplastic agent.

2. The medicament formulation according to claim 1 , wherein the isothiocyanate functional compound comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional compound.

3. The medicament formulation according to claim 1 , wherein the isothiocyanate functional compound comprises a lysine derivative, wherein the lysine derivative comprises an α-nitrogen and a ε-nitrogen, and wherein an alkyl and/or alkanoyl substituent comprising 8 carbon atoms is bound to the α-nitrogen, and further wherein the ε-nitrogen forms part of an isothiocyanate functional group.

4. The medicament formulation according to claim 1 , wherein the protonated form of the isothiocyanate functional compound is represented by the following chemical structure:

wherein R 1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R 2 is selected from the group consisting of NCS; and wherein R 3 -R 5 are each independently selected from the group consisting of H; OH; and an alkyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R 3 -R 5 is selected from the group consisting of an alkyl group containing 8 to 25 carbon atoms.

5. The medicament formulation according to claim 1 , wherein the protonated form of the isothiocyanate functional compound is represented by the following chemical structure:

wherein R 1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R 2 is selected from the group consisting of NCS; and wherein R 3 -R 5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R 3 -R 5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms.

6. The medicament formulation according to claim 5 , wherein the second medicament comprises at least one of a cytotoxic antineoplastic agent and a targeted antineoplastic agent.

7. The medicament formulation according to claim 5 , wherein the second medicament comprises a cytotoxic antineoplastic agent selected from the group comprising a nucleoside analogue, an antifolate, an antimetabolite, a topoisomerase inhibitor, a anthracycline, a podophyllotoxin, a taxane, a vinca alkaloid, an alkylating agent, and/or a platinum compound.

8. The medicament formulation according to claim 5 , wherein the second medicament comprises a monoclonal antibody, a tyrosine kinase inhibitor, an mTOR inhibitor, a retinoid, an immunomodulatory agent, and/or a histone deacetylase inhibitor.

9. The medicament formulation according to claim 5 , wherein the second medicament comprises a DNA-effecting or influencing anti-cancer medicament, a kinase-inhibiting anti-cancer medicament, an anti-androgen medicament and/or a hormonal anti-cancer medicament.

10. The medicament formulation according to claim 5 , wherein the second medicament comprises bicalutamide.

11. The medicament formulation according to claim 5 , wherein the second medicament comprises fluorouacil.

12. The medicament formulation according to claim 5 , wherein the second medicament comprises chlormethine.

13. The medicament formulation according to claim 5 , wherein the second medicament comprises at least one of bevacizumab, cetuximab, denosumab, gemtuzumab ozogamicin, ibritumomab tiuxetan, ipilimumab, nivolumab, ofatumumab, panitumumab, pembrolizumab, pertuzumab, rituximab, tositumomab, and trastuzumab.

14. The medicament formulation according to claim 5 , wherein the second medicament comprises at least one of alitretinoin, bexarotene, isotretinoin, tamibarotene, and tretinoin.

Assignees

• Silver Michael E
• The William M Yarbrough Found

Inventors

• Silver Michael E

Classifications

• A61K31/198

  Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) · CPC title

• A61K31/277

  having a ring, e.g. verapamil · CPC title

• A61K31/26 Primary

  Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P35/00

  Antineoplastic agents · CPC title